TIGIT Blockade Assay

Immunotherapies targeting key immune checkpoints have been developed to facilitate tumor cell elimination. TIGIT is one of the inhibitory receptors that has been focused on immunotherapy discovery. To characterize the functions of anti-TIGIT antibodies, Creative Biolabs has established a panel of cell-based functional assays for effectively investigating the potency and Molecular of Action (MOA) of antibodies and other biologics targeting TIGIT.

Introduction to TIGIT

TIGIT (T cell immunoreceptor with Ig and ITIM domains), also known as WUCAM and Vstm3, containing immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains, is an immune checkpoint protein presented on some T cells and natural killer (NK) cells. It can bind to CD155 (PVR) on macrophages and dendritic cells (DCs) with high affinity, and also to CD112 (PVRL2) with lower affinity. TIGIT has been revealed to play inhibitive roles in T cell activation. Research has reported that TIGIT-Fc fusion protein could bind to PVR on dendritic cells, resulting in an increase of IL-10 secretion or reduction of IL-12 secretion under LPS stimulation. Furthermore, TIGIT is an inhibitory counterpart of the co-stimulatory receptor CD226. TIGIT on the surface of lymphocytes binds with much higher affinity than CD226 to their common ligand, PVR. Thus, TIGIT could outcompete CD226 for PVR binding and negate CD226 co-stimulation. Besides, TIGIT could inhibit CD226 homodimerization in cis, preventing CD226 signaling.

Fig.1 Ligation of TIGIT on Tregs contributes to dampening of anti-tumor immunity.^{1, 2}

TIGIT Blockade Assay at Creative Biolabs

TIGIT blockade assay is a bioluminescent cell-based assay that overcomes the limitations of current methods (e.g. complex assay protocols, unqualified assay reagents, and independent of donor primary cells). This test can be used to measure the potency and stability of antibodies and other biologics targeting functional immune checkpoint TIGIT or PVR, also to elucidate the MOA of biologics. Creative Biolabs is a world-leading service provider for antibody functional assessment. We are confident in offering top-ranking TIGIT blockade assay services for global customers. Our services are characterized by:

• Excellent expert team for offering real-time technical guidance
• Advanced assay platforms to promote the data output
• Timely data feedback to facilitate the process of your project

Hot Products

Creative Biolabs provides a wide array of TIGIT bioassay kits and TIGIT cell lines, specifically designed to support TIGIT characterization and promote the development of cutting-edge therapeutic solutions. Contact us for more details.

Customer Review

As a world-leading service provider of antibody function analysis services, Creative Biolabs has accumulated extensive experience from the accomplishment of different projects, during which we have received a lot of recognition and praise from our clients. We are very proud of providing high-quality, omnidirectional immune checkpoint binding and interaction assay services to our valued clients to remove the difficulties of your projects. For more detailed information, please feel free to contact us or directly sent us an inquiry.

References

1. Ge, Zhouhong, et al. "TIGIT, the next step towards successful combination immune checkpoint therapy in cancer." Frontiers in Immunology 12 (2021): 699895.
2. Distributed under Open Access License CC BY 4.0, without modification.

For Research Use Only.